These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Vilsbøll T; Krarup T; Madsbad S; Holst JJ Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099 [TBL] [Abstract][Full Text] [Related]
4. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405 [TBL] [Abstract][Full Text] [Related]
5. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985 [TBL] [Abstract][Full Text] [Related]
6. The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. Helsted MM; Gasbjerg LS; Lanng AR; Bergmann NC; Stensen S; Hartmann B; Christensen MB; Holst JJ; Vilsbøll T; Rosenkilde MM; Knop FK Bone; 2020 Nov; 140():115553. PubMed ID: 32730920 [TBL] [Abstract][Full Text] [Related]
8. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Meier JJ; Kemmeries G; Holst JJ; Nauck MA Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224 [TBL] [Abstract][Full Text] [Related]
9. Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. Idorn T; Knop FK; Jørgensen M; Holst JJ; Hornum M; Feldt-Rasmussen B Nephrol Dial Transplant; 2014 Jan; 29(1):119-27. PubMed ID: 24078334 [TBL] [Abstract][Full Text] [Related]
10. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780 [TBL] [Abstract][Full Text] [Related]
11. Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1). Ranganath L; Schaper F; Gama R; Morgan L; Wright J; Teale D; Marks V Diabetes Metab Res Rev; 1999; 15(6):390-4. PubMed ID: 10634963 [TBL] [Abstract][Full Text] [Related]
12. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Kielgast U; Holst JJ; Madsbad S Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444 [TBL] [Abstract][Full Text] [Related]
13. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes. Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886 [TBL] [Abstract][Full Text] [Related]
14. Effects of endogenous GIP in patients with type 2 diabetes. Stensen S; Gasbjerg LS; Krogh LL; Skov-Jeppesen K; Sparre-Ulrich AH; Jensen MH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Knop FK Eur J Endocrinol; 2021 May; 185(1):33-45. PubMed ID: 33886495 [TBL] [Abstract][Full Text] [Related]
15. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927 [TBL] [Abstract][Full Text] [Related]